We were delighted to talk with Dr. David Rosmarin (Tufts Medical Center, Boston, MA, USA) to discuss the efficacy and safety findings of the TRuE-V1 and TRuE-V2 studies, investigating ruxolitinib cream monotherapy for the treatment of vitiligo.
The abstract ‘Efficacy and Safety of Ruxolitinib Cream Monotherapy for the Treatment of Vitiligo: Results From Two 52-Week Phase 3 Studies’ was presented at AAD-VMX 2022, 25-29 March.
- What is the rationale for the use of ruxolitinib cream in the treatment of vitiligo? (0:13)
- What were the aims, design and eligibility criteria of the TRuE-V1 and TRuE-V2 studies? (0:45)
- What were the efficacy and safety findings of these studies? (2:00)
- If approved, what will be the impact of ruxolitinib cream on the treatment of patients with vitiligo? (3:16)
- Which patients are most likely to respond to this treatment? (3:40)
- What future studies are planned? (4:24)
Disclosures: David Rosmarin discloses consulting for AbbVie, Abcuro, AltruBio, Arena, Boehringer-Ingelheim, Bristol Meyers Squibb, Celgene, Concert, CSL Behring, Dermavant, Dermira, Incyte, Janssen, Kyowa Kirin, Lilly, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharmaceuticals, UCB, VielaBio; grant/ research support from AbbVie, Amgen, Bristol Meyers Squibb, Celgene, Dermira, Galderma, Incyte, Janssen, Lilly, Merck, Novartis, Pfizer, and Regeneron Pharmaceuticals; and participating in speaker’s bureaus for AbbVie, Amgen, Bristol Meyers Squibb, Celgene, Incyte, Janssen, Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., and Sanofi.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the AAD-VMX annual meeting 2022.
Share this Video
Related Videos In Dermatological Diseases
Victoria P. Werth, ACR 2022: The phase 3 DeterMine trial of lenabasum in dermatomyositis
DeterMine (NCT03813160) was a phase 3 randomized, double-blind, placebo-controlled study investigating the efficacy and safety of lenabasum for the treatment of dermatomyositis. It was a pleasure to talk with Prof. Victoria P. Werth (University of Pennsylvania, Philadelphia, PA, USA) to discuss the aims, design, eligibility criteria and findings of the phase 3 study. This information […]
Loretta Fiorillo, EADV 2022: Findings from the Phase 3 Study of Apremilast in Paediatric Plaque Psoriasis
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. touchIMMUNOLOGY were delighted to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) to discuss the the aims, design and eligibility criteria of the study investigating apremilast in paediatric patients with moderate to severe plaque psoriasis and how […]
Loretta Fiorillo, EADV 2022: Apremilast Treatment for Plaque Psoriasis in Paediatric Patients
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. It was a pleasure to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) around the unmet needs in the treatment of plaque psoriasis in paediatric patients and the clinical evidence supporting apremilast in this indication. The abstract […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!